GSK3B and neoplasm: The activation of GSK3β in colorectal tumors in mice treated with SP contributes to decreased β-catenin expression and to reduced tumor growth as assessed by enhanced apoptosis and reduced [18F]-FDG uptake measured by PET/CT.